Stem cells in Texas: Cowboy culture

Nature (Impact Factor: 41.46). 02/2013; 494(7436):166-8. DOI: 10.1038/494166a
Source: PubMed


By offering unproven therapies, a Texas biotechnology firm has sparked a
bitter debate about how stem cells should be regulated.

2 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is a large, poorly regulated international market of putative stem cell products, including transplants of processed autologous stem cells from various tissues, cell processing devices, cosmetics, and nutritional supplements. Despite the absence of rigorous scientific research in the form of randomized clinical trials to support the routine use of such products, the market appears to be growing and diversifying. Very few stem cell biologics have passed regulatory scrutiny, and authorities in many countries, including the United States, have begun to step up their enforcement activities to protect patients and the integrity of health care markets.
    No preview · Article · Aug 2013 · STEM CELLS TRANSLATIONAL MEDICINE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regenerative medicine has evolved differently in global regions, in part due to policies and funding patterns but also due to their styles of governance within particular historical and political conditions. In this chapter, we review global research climates for stem cell-related research, analyzing infrastructure, governance, and funding patterns. We present considerations for reorienting science policy and research program planning gained from our observations and interviews with researchers in sites in North America, Europe, and Asia. © Springer Science+Business Media New York 2014. All rights are reserved.
    No preview · Article · Oct 2013
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Following the coordinated efforts of five established scientific organizations, this report describes the "novel cellular therapy" activity (i.e., cellular treatments excluding hematopoietic stem cells for the reconstitution of hematopoiesis) in Europe for the year 2011. Two hundred and forty six teams from 35 countries responded to the cellular therapy survey, 126 teams from 24 countries provided data on 1759 patients using a dedicated survey; 120 teams reported no activity. Indications were musculoskeletal/rheumatological disorders (46%; 99% autologous), cardiovascular disorders (22%; 100% autologous), hematology/oncology, predominantly including prevention or treatment of GvHD (18%; 2% autologous), neurological disorders (2%; 83% autologous), gastrointestinal (1%; 68% autologous) and other indications (12%; 77% autologous). Autologous cells were used predominantly for musculoskeletal/rheumatological (58%) and cardiovascular (27%) disorders, whereas allogeneic cells were used mainly for hematology/oncology (84%). The reported cell types were mesenchymal stem/stromal cells (MSC) (56%), hematopoietic stem cells (HSC) (23%), chondrocytes (12%), dermal fibroblasts (3%), keratinocytes (2%) and others (4%). In 40% of the grafts, cells were delivered following ex vivo expansion, whereas cells were transduced or sorted respectively in 3% and 10% of the reported cases. Cells were delivered intraorgan (42%), intravenously (26%), on a membrane or gel (16%) or using 3D scaffolds (16%). As compared to last year, the number of teams participationg in the dedicated survey doubled and, for the first time, all EBMT teams reporting information on cellular therapies completed the extended questionnaire. The data are compared to those collected since 2008 to identify trends in the field. This year's edition specifically focuses on cardiac cell therapy.
    Full-text · Article · Oct 2013 · Tissue Engineering Part A
Show more